Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 10:52 PM ET

Biotechnology

Company Overview of Apellis Pharmaceuticals, Inc.

Company Overview

Apellis Pharmaceuticals, Inc., an early stage biotechnology company, applies immunotherapy to auto-immune diseases. The company focuses on developing complement immunotherapies for diseases of the lungs, such as asthma and chronic obstructive pulmonary disease; diseases of the retina, including age-related macular degeneration; and rare hematological diseases, such as paroxysmal nocturnal hemoglobinuria. Its drug compound, APL-2, is used in patients suffering from age-related macular degeneration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

6400 Westwind Way

Suite A

Crestwood, KY 40014

United States

Founded in 2009

Phone:

502-241-4114

Key Executives for Apellis Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Chief Operating Officer
Co-Founder and Vice-President of Clinical Development
Co-Founder and Director
Age: 42
Vice-President of Corporate Development and General Counsel
Compensation as of Fiscal Year 2015.

Apellis Pharmaceuticals, Inc. Key Developments

Apellis Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board

Apellis Pharmaceuticals, Inc. announced the formation of a Scientific Advisory Board. Carl Atkinson, PhD. Assistant Professor Microbiology & Immunology, Medical University of South Carolina, USA. Robert A. Brodsky, MD. Director, Division of Hematology, Professor of Medicine and Oncology, Johns Hopkins Hospital, USA. Gabriel J. Coscas, MD. Professor and Chairman of Ophthalmology, University of Paris XII, France. Peter Hillmen, MD, PhD. Professor of Experimental Hematology, Leeds Institute of Cancer & Pathology, UK. Claudia Kemper, PhD. Faculty, King's College, UK. Susan M. Lea, PhD. Chair and Professor of Microbiology, Co-Director, Oxford Martin Programme on Vaccines, Sir William Dunn School of Pathology, UK. Toby Maher, MD, PhD. Clinician Scientist, Pulmonologist and Honorary Senior Lecturer, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, UK. Philip J. Rosenfeld, MD, PhD. Professor of Ophthalmology, Bascom Palmer Eye Institute, USA. Johanna M. Seddon, MD, ScM. Professor of Ophthalmology, Tufts University School of Medicine, Boston, USA. Dave Singh, MD. Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, UK. Jason S. Slakter, MD.Vitreous Retina Macular Consultants of New York and Clinical Professor of Ophthalmology, New York University School of Medicine, USA. Janet S. Sunness, MD. Medical Director of Richard E. Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, USA. Marsha Wills-Karp, PhD. Professor, Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, USA. Mike Yeadon, PhD. President and CEO, Ziarco, UK.

Apellis Pharmaceuticals, Inc. Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program

Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal injections of APL-2 and will be conducted in patients afflicted with wet AMD at multiple sites in the United States and Australia. The company plans to follow ASAP II with a larger Phase II trial in patients with geographic atrophy (the advanced stage of dry AMD) in the late spring of 2015.

Similar Private Companies By Industry

Company Name Region
Proviera Biotech, LLC United States
Arcxis Biotechnologies, Inc. United States
Amulet Pharmaceuticals, Inc. United States
Power 3 Medical Products Inc. United States
ALS Biopharma, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 5, 2014
--
Private Placement
December 2, 2014
--
Merger/Acquisition
November 20, 2014
Potentia Pharmaceuticals, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Apellis Pharmaceuticals, Inc., please visit www.apellis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.